VBI Vaccines Provides Update on Part A of Ongoing Phase 1/2a Study Demonstrating Overall Survival Benefit for VBI-1901 Vaccine Responders in Recurrent GBM Patients
Stock Information for VBI Vaccines Inc.
Loading
Please wait while we load your information from QuoteMedia.